{
  "meta": {
    "timestamp": "2025-01-06T13:36:49.095364",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID",
      "symbol": "BXPHF",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Regulatory Risks: Significant hurdles with FDA and TGA approvals could delay or derail product pipelines.",
            "Clinical Trial Uncertainties: Adverse events or failure to meet endpoints in ongoing trials could negatively impact prospects.",
            "Financial Dependence: Heavy reliance on external funding, including equity offerings, poses risks if capital is not secured.",
            "Market Competition: Highly competitive dermatology and antimicrobial markets may challenge market share acquisition.",
            "Dependence on Synthetic CBD: Reliance on synthetic CBD technology could be risky if regulatory or public perception shifts unfavorably."
          ],
          "controversies": [
            "Escrow Restrictions: 156.5 million shares remain subject to escrow until July 2018, limiting liquidity for certain investors.",
            "No Franking Credits: The company does not pay dividends and has a 0% franking level, indicating no taxable profits distributed to shareholders."
          ],
          "environmental_issues": [],
          "social_issues": [
            "Synthetic CBD Focus: Use of pharmaceutical-grade synthetic cannabidiol (CBD) differentiates the company but may face public perception challenges."
          ],
          "governance_issues": [
            "Reinstatement on ASX: Securities were reinstated to official quotation in 2016 after compliance with ASX listing rules, reflecting past governance issues."
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Issues New Shares Amid FDA Approval",
              "snippet": "Botanix Pharmaceuticals Limited has issued 166,666 new fully paid ordinary shares, allowing them to be traded immediately under an exemption in the Corporations Act. This expansion follows the ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:31.546223+00:00",
              "published_date": "2024-12-02T09:36:00+00:00",
              "source_hash": "1392e100e315bfb9d446314383618662"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Issues New Shares Amid FDA Approval",
              "snippet": "Botanix Pharmaceuticals Limited (AU:BOT) has released an update. Don't Miss our Black Friday Offers: Botanix Pharmaceuticals Limited has issued 166,666 new fully paid ordinary shares, allowing ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205750+00:00",
              "published_date": null,
              "source_hash": "ff026da6b1b65e15459729e4a3c7c504"
            },
            {
              "url": "",
              "title": " Botanix Pharmaceuticals Limited (\"Botanix\" or For personal use only",
              "snippet": "Botanix Pharmaceuticals Ltd Vesparum Capital ... Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Include recently completed placement (A$7.4m). Excludes 47.9m unlisted options with exercise price range of A$0.03 - A$0.07 and expiry date range of Jan 2018 to May 2020 ... Botanix is fully funded for the Phase Ib ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912503+00:00",
              "published_date": null,
              "source_hash": "c405d8d254f3b2199372bf0010dffc3f"
            },
            {
              "url": "",
              "title": " Key highlights For personal use only engaging with Botanix while ...",
              "snippet": "Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to announce that it has received a firm commitment from a new institutional investor for a placement of approximately 79.4 million new fully paid ordinary shares (\"New Shares\") at A$0.063 per New Share (\"Placement Price\")",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912515+00:00",
              "published_date": null,
              "source_hash": "6c73b8630268c9ffdff2ea9322c80829"
            },
            {
              "url": "",
              "title": " Investor Presentation March 2017 - botanixpharma.com",
              "snippet": "Botanix Pharmaceuticals Ltd. 2 Investment highlights Experienced US based leadership team in place with a proven track record of achieving FDA approvals ... Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Excludes 38.8m unlisted options with exercise price range of A$0.03 - A$0.133 and expiry date range of Dec ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912525+00:00",
              "published_date": null,
              "source_hash": "ff62620e6f6d546e494bedc89ddd1eda"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Lists New Securities on ASX - Nasdaq",
              "snippet": "Botanix Pharmaceuticals Ltd has announced the quotation of 166,666 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 2, 2024.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205623+00:00",
              "published_date": null,
              "source_hash": "c0f297065b30975c68c3325c3e20aa90"
            },
            {
              "url": "",
              "title": " Botanix Pharmaceuticals Quarterly Activity Report and 4C Quarterly Cash ...",
              "snippet": "104,166,667 new fully paid ordinary shares at A$0.12 per New Share (Placement). These new shares issued under the Placement rank pari passu with existing Botanix fully paid ordinary shares from their date of issue. Proceeds from the Placement have been primarily used to extinguish the future milestone and royalty",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912543+00:00",
              "published_date": null,
              "source_hash": "19eb239422bb71aa9d6db869b77b3c76"
            },
            {
              "url": "",
              "title": " Botanix Pharmaceuticals Quarterly Activity Report and 4C Quarterly Cash ...",
              "snippet": "During the quarter, Botanix welcomed the investment of $12.5 million from new and existing institutional and sophisticated investors pursuant to a placement of 104,166,667 new fully paid ordinary shares at A$0.12 per New Share (Placement). These new shares issued under the Placement",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912552+00:00",
              "published_date": null,
              "source_hash": "07986bada9b92800a81969f71918190f"
            },
            {
              "url": "",
              "title": " Botanix completes successful A$7.5m placement to Australian and ...",
              "snippet": "Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to that the announce Company has received firm commitments from new and existing institutional and sophisticated investors for the placement of 113,636,364 fully paid ordinary shares (\"New Shares\") at A$0.066 per",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912560+00:00",
              "published_date": null,
              "source_hash": "32543eda4e339b4d2b62d06a50210964"
            },
            {
              "url": "",
              "title": " For personal use only - botanixpharma.com",
              "snippet": "Botanix Pharmaceuticals Ltd. 3 Capital raising overview ... Development of BTX 1701 (acne cleanser/wash), that does not require FDA approval, allows Botanix to potentially generate ... Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Excludes 38.8m unlisted options with exercise price range of A$0.03 - A$0.133 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:15.912569+00:00",
              "published_date": null,
              "source_hash": "73f19b6a3bc7f06388049dce0ecec423"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Issues New Shares Amid FDA Approval",
              "snippet": "Botanix Pharmaceuticals ... new fully paid ordinary shares, allowing them to be traded immediately under an exemption in the Corporations Act. This expansion follows the recent FDA approval ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:20.535588+00:00",
              "published_date": "2024-12-02T09:36:00+00:00",
              "source_hash": "3543dc34ca10a9ffd17dee8024a62bdf"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Lists New Securities on ASX",
              "snippet": "Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Botanix Pharmaceuticals Ltd has announced the quotation of 166,666 ordinary fully paid securities on the ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:31.546248+00:00",
              "published_date": "2024-12-02T09:26:00+00:00",
              "source_hash": "6f4406b7add39bf91e23a96eb5b19833"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Ltd (ASX: BOT) - Share Price and Research",
              "snippet": "Botanix Pharmaceuticals Ltd (BOT) has a franking level of 0%. Franking represents the tax Botanix Pharmaceuticals Ltd (BOT) has already paid on any profit it distributes to shareholders as a dividend. When does Botanix Pharmaceuticals Ltd (BOT) release its ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:31.546256+00:00",
              "published_date": "2024-12-10T22:21:00+00:00",
              "source_hash": "2a6da60e5a5055236b68a3eeca02df13"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Expands Sofdra\u2122 Coverage in US",
              "snippet": "Botanix Pharmaceuticals Limited (AU:BOT) has released an update. Botanix Pharmaceuticals has secured coverage for its FDA-approved Sofdra\u2122 topical gel with Ascent Health, the second-largest ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "retrieved_at": "2025-01-06T20:36:20.535652+00:00",
              "published_date": "2024-11-14T00:59:00+00:00",
              "source_hash": "fc5e86bc09281205e511a92d4a8c0cfb"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to announce that it has received firm commitments from new and existing institutional and sophisticated investors for 104,166,667 new fully paid ordinary shares (\"New Shares\") at A$0.12 per New Share (\"Placement",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:22.538478+00:00",
              "published_date": null,
              "source_hash": "e4bda91b8740acc639ca5ea63bd16c07"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "104,166,667 new fully paid ordinary shares at A$0.12 per New Share (Placement). These new shares issued under the Placement rank pari passu with existing Botanix fully paid ordinary shares from their date of issue. Proceeds from the Placement have been primarily used to extinguish the future milestone and royalty",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:22.538488+00:00",
              "published_date": null,
              "source_hash": "9b41f453acfb9e7630fb43c5106e079e"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Philadelphia and Phoenix US, 27 July 2022: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to announce that the Company has closed its $12.5 million placement to new and existing institutional and sophisticated investors for the placement of 104,166,667 new fully paid ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:22.538497+00:00",
              "published_date": null,
              "source_hash": "37413cfb202b444b208e1240f413bc1f"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to announce that it has received a firm commitment from a new institutional investor for a placement of approximately 79.4 million new fully paid ordinary shares (\"New Shares\") at A$0.063 per New Share (\"Placement Price\")",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205733+00:00",
              "published_date": null,
              "source_hash": "fe8d4115cf3daa8f425fb7e17795dd5b"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to that the announce Company has received firm commitments from new and existing institutional and sophisticated investors for the placement of 113,636,364 fully paid ordinary shares (\"New Shares\") at A$0.066 per",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:22.538522+00:00",
              "published_date": null,
              "source_hash": "8e166d8d55486c08eb23f2bbe88120fa"
            },
            {
              "url": "",
              "title": "Cleansing Notice - Placement and Share Purchase Plan - Botanix ...",
              "snippet": "7 November 2022 Cleansing Notice Under Section 708A(5)(e) of the Corporations Act 2001 and ASIC Corporations (Share And Interest Purchase Plans) Instrument 2019/547 Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\") wishes to confirm the issue of 70,717,484 million fully paid ordinary shares in the Company (New Shares) on 7 November ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:22.538530+00:00",
              "published_date": null,
              "source_hash": "7f7cf4bfcd732698168a25e46c00ff27"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Pharmaceuticals Limited (ASX: BOT, \"Botanix\" or \"the Company\"), is pleased to that announce the Company has closed the first tranche of its $7.5 million placement to new and existing up to institutional and sophisticated investors for the placement of up to 113,636,364 fully paid ordinary",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:22.538540+00:00",
              "published_date": null,
              "source_hash": "5f59934ac1d79407fd7e123fd100ec14"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals: Director's Stock Interests Surge",
              "snippet": "Botanix Pharmaceuticals Limited (AU:BOT) has released an update. Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:24.616946+00:00",
              "published_date": "2024-12-03T12:39:00+00:00",
              "source_hash": "5dd56eb44f451bee70f76117875ce97e"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Prepares for Sofdra\u2122 Market Launch",
              "snippet": "Botanix Pharmaceuticals Limited ... shipping first prescriptions to patients. The company has ramped up its inventory and logistics to support a full commercial launch in early 2025, while ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "retrieved_at": "2025-01-06T20:36:24.616955+00:00",
              "published_date": "2024-12-16T16:19:00+00:00",
              "source_hash": "9886ab0ec55291f84418fd81537e754a"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Botanix Pharmaceuticals Ltd. 2 ... Key products based on pharmaceutical grade synthetic cannabidiol (versus variable naturally derived cannabidiol), greatly enhances the probability of clinical development success ... Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Excludes 38.8m unlisted options with exercise ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205674+00:00",
              "published_date": null,
              "source_hash": "318e746fb6dd0826b2818e220127e301"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Ltd (formerly Bone Medical Ltd) - Reinstatement ...",
              "snippet": "The securities of Botanix Pharmaceuticals Ltd (formerly Bone Medical Ltd) (the \"Company\") were suspended from Official Quotation on 14 June 2016. The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Friday 15 July 2016 following the Company's compliance with Listing Rule 11.1.3 and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205687+00:00",
              "published_date": null,
              "source_hash": "dbcf2e8de2eb2a333b7b53913973653f"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Botanix Pharmaceuticals Ltd. 3 Capital raising overview ... Key products based on pharmaceutical grade synthetic cannabidiol (versus variable naturally derived cannabidiol), greatly enhances the probability of clinical and regulatory success ... Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Excludes 38.8m ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205698+00:00",
              "published_date": null,
              "source_hash": "6597626c7d089de91fa0071b4c98335c"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "BOTANIX PHARMACEUTICALS LTD We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. 1.2 Registered number type ABN Registration number 70009109755 1.3 ASX issuer code BOT 1.4 The announcement is 1.5 Date of this announcement 12/12/2022",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205707+00:00",
              "published_date": null,
              "source_hash": "d41bee0a81e773032df9dadcf5641c33"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Botanix Pharmaceuticals Ltd Vesparum Capital ... Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Include recently completed placement (A$7.4m). Excludes 47.9m unlisted options with exercise price range of A$0.03 - A$0.07 and expiry date range of Jan 2018 to May 2020 ... Synthetic cannabidiol Naturally ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205725+00:00",
              "published_date": null,
              "source_hash": "1a4dd9850a0d9fe6c6a2e7f790c969ea"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Ltd (ASX:BOT) - Intelligent Investor",
              "snippet": "Relative to the previous close share price of $0.40, Botanix Pharmaceuticals Ltd's (BOT) current share price of $0.40 constitutes a movement of or 0%. Botanix Pharmaceuticals Ltd's (BOT) share price movement is 3.95% when compared to 7 days ago and is -9.20% below BOT's 52-week high of $0.44.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:28.205742+00:00",
              "published_date": null,
              "source_hash": "2533c1e820845f747d36497ff6c281aa"
            },
            {
              "url": "",
              "title": "Botanix Pharmaceuticals Prepares for Sofdra\u2122 Market Launch",
              "snippet": "Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Botanix Pharmaceuticals Limited ... and logistics to support a full commercial launch in early 2025, while ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "retrieved_at": "2025-01-06T20:36:31.546261+00:00",
              "published_date": "2024-12-16T22:19:00+00:00",
              "source_hash": "0782dc973d4580b1b83b23158c3f0e6c"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID regulatory delays FDA",
              "rationale": "Investigate potential delays or rejections in FDA approvals for clinical trials or product commercialization",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID funding risks capital raises",
              "rationale": "Assess risks related to the company's dependence on external funding and investor sentiment",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "BOTANIX PHARMACEUTICALS LTD ORDINARY FULLY PAID synthetic CBD public perception controversies",
              "rationale": "Explore public or regulatory concerns regarding synthetic CBD-based products",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T13:36:49.095371",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}